Wyeth Targets Zydus In New Effexor XR Patent Suit

Law360, New York (April 13, 2009, 12:00 AM EDT) -- In its latest effort to block a generic version of Effexor XR, Wyeth has accused Indian drugmaker Cadila Healthcare Ltd. and its U.S.-based subsidiary, Zydus Pharmaceuticals USA Inc., of infringing three patents related to the popular antidepressant.

The complaint, filed Friday in the U.S. District Court for the District of Delaware, alleges that Cadila and its New Jersey-based unit, Zydus, worked together to file an abbreviated new drug application with the U.S. Food and Drug Administration to sell an extended-release form of venlafaxine hydrochloride.

Cadila developed...
To view the full article, register now.